========================================================================
  PGx CLINICAL SOLUTIONS — VALIDATION & IMPACT REPORT
  Ernest Moyo | Rangarirai Makuku | Tapiwa Mupereki | Ngonidzashe Faya
========================================================================

VALIDATION SUMMARY
----------------------------------------
  Total test cases:             12
  Cases passed:                 12/12
  Individual checks passed:     15/15
  Overall accuracy:             100.0%
  Finding sensitivity:          100.0%
  Critical detection rate:      100.0%

PER-CASE RESULTS
----------------------------------------
  [+] TC01: CYP2C19 PM on citalopram — dose reduction required
      Area: psychiatry | Findings: 1 | Recs: 1 | Status: PASS
        - Should flag dose reduction to max 20mg/day: OK
          Matched: citalopram | CYP2C19 | high | score=84.5

  [+] TC02: CYP2D6 UM on codeine — AVOID (life-threatening toxicity)
      Area: pain_management | Findings: 1 | Recs: 1 | Status: PASS
        - Must flag CONTRAINDICATED — fatal toxicity risk: OK
          Matched: codeine | CYP2D6 | critical | score=100.0

  [+] TC03: VKORC1 A/A + CYP2C9 PM on warfarin — major dose reduction
      Area: cardiology | Findings: 2 | Recs: 1 | Status: PASS
        - VKORC1 high sensitivity — major reduction: OK
          Matched: warfarin | VKORC1 | critical | score=100.0
        - CYP2C9 PM — major reduction: OK
          Matched: warfarin | CYP2C9 | critical | score=100.0

  [+] TC04: CYP2C19 PM on clopidogrel — switch to prasugrel/ticagrelor
      Area: cardiology | Findings: 1 | Recs: 1 | Status: PASS
        - Must switch to prasugrel or ticagrelor: OK
          Matched: clopidogrel | CYP2C19 | critical | score=100.0

  [+] TC05: DPYD PM on fluorouracil — CONTRAINDICATED (fatal toxicity)
      Area: oncology | Findings: 1 | Recs: 1 | Status: PASS
        - CONTRAINDICATED — fatal toxicity: OK
          Matched: fluorouracil | DPYD | critical | score=100.0

  [+] TC06: SLCO1B1 poor function on simvastatin — switch statin
      Area: cardiology | Findings: 1 | Recs: 1 | Status: PASS
        - AVOID simvastatin — rhabdomyolysis risk: OK
          Matched: simvastatin | SLCO1B1 | critical | score=100.0

  [+] TC07: CYP2D6 PM on tamoxifen — switch to aromatase inhibitor
      Area: oncology | Findings: 1 | Recs: 1 | Status: PASS
        - Switch to aromatase inhibitor: OK
          Matched: tamoxifen | CYP2D6 | critical | score=100.0

  [+] TC08: CYP2D6 PM + fluoxetine DDI on codeine — dual flag
      Area: pain_management | Findings: 2 | Recs: 2 | Status: PASS
        - Gene: CYP2D6 PM — codeine ineffective: OK
          Matched: codeine | CYP2D6 | critical | score=100.0
        - DDI: fluoxetine inhibits CYP2D6: OK
          Matched: fluoxetine + codeine | CYP2D6 | high | score=84.5

  [+] TC09: CYP2C19 PM on clopidogrel + omeprazole DDI — dual flag
      Area: cardiology | Findings: 2 | Recs: 2 | Status: PASS
        - Gene: CYP2C19 PM — clopidogrel ineffective: OK
          Matched: clopidogrel | CYP2C19 | critical | score=100.0
        - DDI: omeprazole inhibits CYP2C19: OK
          Matched: omeprazole + clopidogrel | CYP2C19 | high | score=84.5

  [+] TC10: TPMT PM on mercaptopurine — 90% dose reduction
      Area: oncology | Findings: 1 | Recs: 1 | Status: PASS
        - Reduce to 10% of standard dose: OK
          Matched: mercaptopurine | TPMT | critical | score=100.0

  [+] TC11: UGT1A1 *28/*28 on irinotecan — 30% dose reduction
      Area: oncology | Findings: 1 | Recs: 1 | Status: PASS
        - Reduce irinotecan dose by 30%: OK
          Matched: irinotecan | UGT1A1 | critical | score=100.0

  [+] TC12: HLA-B*15:02 positive on carbamazepine — CONTRAINDICATED (SJS/TEN)
      Area: psychiatry | Findings: 1 | Recs: 1 | Status: PASS
        - CONTRAINDICATED — SJS/TEN risk: OK
          Matched: carbamazepine | HLA-B | critical | score=100.0

CLINICAL IMPACT METRICS
----------------------------------------
  Adverse events preventable:   26
  Cost avoided per event:       $25,000
  Total cost avoidance:         $650,000
  Time saved per report:        2.2 hours
  Analyst capacity improvement: 10x (from ~1,000 to ~10,000 reports per analyst per year)

VALUE PROPOSITION SUMMARY
----------------------------------------
  Automated interpretation vs. manual pharmacist review:
    - Speed: <1 minute (automated) vs 2-3 hours (manual)
    - Consistency: 100.0% guideline concordance
    - Critical safety: 100.0% detection of life-threatening interactions
    - Scalability: 10x throughput improvement per analyst
    - Cost: ~$5-15/report (automated) vs ~$150-300/report (manual)

  Therapeutic area coverage validated:
    - cardiology: 4/4 scenarios passed
    - oncology: 4/4 scenarios passed
    - pain_management: 2/2 scenarios passed
    - psychiatry: 2/2 scenarios passed

========================================================================